4//SEC Filing
Nassif David W. 4
Accession 0001209191-19-040520
CIK 0001636050other
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 6:15 PM ET
Size
8.9 KB
Accession
0001209191-19-040520
Insider Transaction Report
Form 4
Nassif David W.
Principal Financial Officer
Transactions
- Award
Stock Option ( Right to Buy)
2019-07-01+75,000→ 75,000 totalExercise: $6.42Exp: 2029-06-30→ Common Shares (75,000 underlying) - Award
Stock Option (Right to Buy)
2019-07-01+150,000→ 150,000 totalExercise: $6.42Exp: 2029-06-30→ Common Shares (150,000 underlying)
Footnotes (3)
- [F1]The option vests over a period of four years, with 25% of the common shares underlying the option vesting on July 1, 2020 and the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date.
- [F2]The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.
- [F3]One-third of the option will vest at such time as the Issuer's 30-day trailing volume weighted average closing stock price ("30-day VWAP") is equal to $12.84; one-third of the option will vest at such time as the Issuer's 30-day VWAP stock price is equal to $25.68; and one-third of the option will vest at such time as the Issuer's 30-day VWAP stock price is equal to $38.52, in each case subject to the Reporting Person providing continuous service to the Issuer on each such date.
Documents
Issuer
Axovant Gene Therapies Ltd.
CIK 0001636050
Entity typeother
Related Parties
1- filerCIK 0001636975
Filing Metadata
- Form type
- 4
- Filed
- Jul 1, 8:00 PM ET
- Accepted
- Jul 2, 6:15 PM ET
- Size
- 8.9 KB